Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Oct 15;212(8):1232-6.
doi: 10.1093/infdis/jiv213. Epub 2015 May 12.

Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study

Xue-en Liu  1 , Hai-ying Chen  2 , Zheng Liao  2 , Yisheng Zhou  2 , Hairong Wen  2 , Shihui Peng  2 , Yan Liu  3 , Rui Li  1 , Jie Li  1 , Hui Zhuang  1
Affiliations
Randomized Controlled Trial

Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study

Xue-en Liu et al. J Infect Dis. .

Abstract

A randomized clinical trial of hepatitis A vaccines (1 or 2 doses of inactivated vaccine [Healive] or 1 dose of live attenuated vaccine [Biovac]) was conducted among adults to evaluate seroprotection rates and geometric mean concentrations of antibody against hepatitis A virus for 36 months. High rates of seroprotection persisted for at least 36 months among adults who received 1 or 2 doses of inactivated hepatitis A vaccine but not among adults who received 1 dose of live attenuated hepatitis A vaccine. The long-term serial monitoring of immunogenicity induced by 1 dose of inactivated hepatitis A vaccine is needed to determine an effective alternative to a 2-dose schedule.

Clinical trials registration: NCT01865968.

Keywords: immunogenicity; inactivated hepatitis A vaccine; live attenuated hepatitis A vaccine.

PubMed Disclaimer

Publication types

Associated data